The FDA approved Eli Lilly’s interleukin-23p19 antagonist Omvoh (mirikizumab-mrkz) as a once-monthly single-injection maintenance option for adults with moderately to severely active ulcerative colitis.
A 30-year-old man with no prior medical history developed cardiogenic shock shortly after eating a tuna sandwich. He experienced central, burning chest pain, diaphoresis, and generalized pruritus. His pain worsened with breathing and did not respond to nitroglycerin.
Roche's anti-CD20 antibody improved renal response and allowed for lower corticosteroid use in the phase III REGENCY trial, offering a twice-yearly maintenance option after initial dosing.